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The role of the pulmonary veins (PVs) in initiating (1,2) and
maintaining (3,4) paroxysms of atrial ﬁbrillation (AF) has
been well documented. The fact that the arrhythmia can be
eliminated in w90% of patients undergoing antral PV
isolation (5) also speaks to the critical role of the thoracic veins
in patients with paroxysmal AF. However, these outcomes are
attained at the expense of repeat procedures, most often for
PV reconnection. Although these results are encouraging and
can be realized with a low risk of complications at experienced
centers, the potential for late recurrence years after the abla-
tion procedure is sobering (6). In an effort to improve
outcomes, several adjunctive targets have been promulgated,
including complex, fractionated atrial electrograms (CFAEs)
(7), left atrial (LA) linear lesions (8), non-PV ectopy, and the
intrinsic cardiac autonomic nervous system (ANS) (9).
Identiﬁcation of driver as opposed to passive sites remains
problematic with CFAE mapping (10), with the result that
we probably end up ablating too much atrial tissue. Linear
lesions are very effective in eliminating AF but at a cost of LA
re-entry, which frequently requires repeat procedures (11).
Patients who require ablation of non-PV foci may fare worse
than those undergoing PV isolation (12).See page 2318The intrinsic cardiac ANS is composed of multiple
ganglionated plexi (GP), which are located in the fat pads on
the epicardial aspect of the atria. These include the anterior
right GP located at the right superior PV-LA junction, the
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PV-LA junction, and the inferior left GP located near the
left inferior PV-LA junction. The extrinsic cardiac ANS,
made up of ganglia from the brain and spinal cord and their
axons destined for the heart, modulates sinoatrial and
atrioventricular nodal function and inﬂuences AF induc-
ibility through the GPs (13). In animal models, stimulation
of the GPs results in rapid, repetitive discharges from the
PVs, and autonomic denervation suppresses this ﬁring (14).
It is hypothesized that AF may develop in humans on the
basis of a “hyperactive” intrinsic cardiac ANS.
The initial clinical studies incorporating the GPs into
conventional LA ablation showed very good outcomes (15).
The GPs were identiﬁed by eliciting a parasympathetic
response (bradycardia/hypotension) during high-frequency
stimulation (HFS). However, studies using a GP-only
approach were met with disappointment. In part, this was
attributed to the suboptimal sensitivity of HFS in identi-
fying the extent of GPs. Currently, an anatomic approach to
GP ablation is preferred, i.e., one in which the atrial tissue
subjacent to the general location of the GPs is targeted
without the need for demonstrating bradycardia or hypo-
tension with HFS (16).
In this issue of the Journal, Katritsis et al. (17) sought to
determine the incremental beneﬁt of GP ablation in patients
undergoing PV isolation for paroxysmal AF. Patients were
randomized to antral PV isolation or antral PV isolation
combined with GP ablation. In addition, a GP-only group
was also included. Only GPs that are likely to be encoun-
tered along the circumference of the antral lesion set were
targeted to decrease the likelihood of gaps and pro-
arrhythmia. There was no requirement for the demon-
stration of a parasympathetic response, but if it was
encountered, the endpoint, in addition to voltage reduction,
included its abolition. After a single procedure and a follow-
up period of 2 years, 74% of patients in the PVþGP group
remained arrhythmia free compared with 56% of the
patients in the PV-only group and 48% in the GP-only
group. In one half of the study population, rhythm status
was assessed by an implantable loop recorder. The mean
radiofrequency duration in the PVþGP, PV-only, and GP-
only groups was 67 min, 41 min, and 46 min, respectively.
There were no complications attributable to GP ablation
and the incidence of post-ablation atrial tachycardia, in
contradistinction to a previous study (9), was not increased.
The investigators should be lauded for contributing
a well-conceived randomized study to a discipline that has
been guided by only a handful of such studies. Their
endeavor further supports the role of the intrinsic cardiac
ANS in the pathophysiology of paroxysmal AF. How might
autonomic denervation lead to improved outcomes in
patients undergoing PV isolation? Because GP ablation was
anchored to the antral lesion set, it is possible that it results
in more durable PV isolation. However, studies using
a GP-only approach have noted that the PVs are rarely
isolated (18). If one assumes that the rate of PV
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2327reconnection is similar in the PVþGP and the PV-only
groups, then the additional LA ablation in the former
must be playing a role. It is possible that although the PVs
may be connected and capable of focal ﬁring, elimination of
the adjacent GP by ablation may render the PV incapable of
initiating AF. In an animal study, activation of the GP was
required to convert PV ﬁring into AF, and injection of
lidocaine, a neuronal blocker, into the GP prevented AF
induction (19). Further, in an experimental model of vagally
mediated AF, ganglion-sparing PV ablation had no effect on
AF maintenance, whereas epicardial ablation of both left-
and right-sided GPs rendered AF noninducible (20). The
antiarrhythmic effect of neural ablation may in part be due to
its effect in preventing abbreviation and dispersion of atrial
refractorinessdfactors that favor re-entrydduring vagal
stimulation.
How well these experimental models relate to human AF
is unknown. Given the paucity of mechanistic data in
humans, we must rely on animal models in hopes of building
a framework that helps us understand how GP ablation leads
to salutary outcomes in patients. To this end, several critical
questions may be raised. Because the GPs are epicardial
structures, can we even be sure that endocardial ablation is
sufﬁcient in eliminating the neural activity in the epicar-
dium? Is it possible that we are instead targeting driver sites
in the form CFAEs or discrete sources (21) that happen to
colocalize to endocardial areas underlying the GPs? How
does the hyperactive GP hypothesis account for structural
remodeling in patients with paroxysmal AF even in the
absence of obvious heart disease (22)? Although a single
procedure success rate of 74% is impressive, what about the
remaining one-fourth of the patients? Might they beneﬁt
from right atrial GP ablation or a more deﬁnitive ablation of
the ligament of Marshall, which also contains autonomic
elements? Perhaps the mechanism in these patients is not
related to the intrinsic cardiac ANS. What of the difﬁculty
in achieving complete denervation, the possibility of rein-
nervation and end-organ hypersensitivity, and the long-term
effects of neural imbalance (23)?
Apart from these far-reaching questions, several practical
issues remain that also need to be sorted out before we can
adopt GP ablation. Relatively high power settings (up to
35 W with an irrigated-tip catheter for as long as 40 s) were
used in this study, presumably in an attempt to target the
epicardial location of the GPs. Although no evidence of
collateral damage was found in this study of 240 patients,
there remains a concern for myocardial injury and perfora-
tion, esophageal injury (during ablation of the inferior GPs),
injury to the phrenic nerve and atrial arteries (24) (during
ablation of the anterior right GP), and gastric hypomotility
(25). If all 4 GPs cannot be ablated because of safety concerns
(e.g., unfavorable esophageal course), data from animal
studies suggest that the resultant partial denervation may not
only be inefﬁcacious (20) but also proarrhythmic (26).
There is little doubt that the standard antral lesion set
results in at least some modiﬁcation of the intrinsic cardiacANS. The appeal of formally adding GP ablation to our
current approach is its simplicity and the fact that it does not
require additional tools or technology. The potential
downside is that we continue down the path of empiricism
and more tissue destruction, albeit guided by the prospect of
better outcomes. Recent studies have raised the possibility
that sources of AF may be discrete and may be eliminated
without extensive ablation (21). Until the age of mechanistic
AF ablation arrives, we are left to decide on which adjunct,
be it CFAEs, non-PV foci, contact force technologies, and
now the GPs, might best prevent recurrence after PV
isolation. At the very least, the excellent contribution by
Katritsis et al. (17) should make us question our current
practice and exhort us to pursue novel strategies in an effort
to improve the lives of our patients with AF. And that’s
a good thing.
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